title: [Low-molecular-weight heparin in unstable angina pectoris].
abstract: We studied the therapeutic effect of standard heparin (HS) compared with low-molecular-weight (HBPM) in two homogeneous groups of 14 patients heparin selected at random, with clinical history and electrocardiographic signs of unstable angina pectoris. Patients received the conventional treatment with platelets' inhibitors, nitrates, adrenergic beta-blockers or calcium antagonists. Both heparins, separately, showed statistical therapeutic effect on the symptoms and signs of unstable angina pectoris. They decreased to zero the number and duration of symptomatic myocardial ischemic events observed by ambulatory electrocardiogram (EKG-Holter). The symptoms of the angina pectoris disappeared at the same elapsed time: in 51.9 +/- 20.2 min. for the HS, and in 48.14 +/- 20.7 min. for the HBPM. They decreased the frequency of the silent myocardial ischemia observed at the EKG-Holter: 9 events decreased to 4 with the HS, and 8 events decreased to 3 with the HBPM. They decreased the total elapsed time of the silent ischemia from 52 min. to 15 min., and the mean elapsed time of the silent ischemia decreased from 3.71 +/- 3.29 min. to 1.07 +/- 1.81 min. with the HS (P < 0.001). With HBPM it decreased the total elapsed time of the silent ischemia from 60 min to 10 min, and the mean elapsed time of the silent ischemia decreased from 4.28 +/- 4.49 min. to 0.71 +/- 1.43 min. (P < 0.02). Both heparins considerably decreased the frequency of the lethal arrhythmias. Although in this study we did not find statistical differences in the therapeutic action of either heparins, HBPM reduced rapidly angina symptoms and the events associated to angina pectoris, cardiac arrhythmias, specially lethal extrasystolia, conduction defects and atrial paroxysmal tachycardia. Compared to HS, HBPM is easily applied, does not produce side effects on coagulation or bleeding time.
authors.affiliation: Departamento de Cardiología, Hospital de Especialidades, Centro Médico La Raza, IMSS, México, D.F.
authors.forename: S
authors.initials: S
authors.lastname: Ocampo
authors.forename: S
authors.initials: S
authors.lastname: Solorio
authors.forename: A
authors.initials: A
authors.lastname: Rangel
authors.forename: F J
authors.initials: FJ
authors.lastname: León
authors.forename: L
authors.initials: L
authors.lastname: Lepe
authors.forename: F
authors.initials: F
authors.lastname: Ayala
authors.forename: R
authors.initials: R
authors.lastname: Madrid
authors.forename: M A
authors.initials: MA
authors.lastname: Romero
authors.forename: A M
authors.initials: AM
authors.lastname: Carrillo
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy*; D016009:Chi-Square Distribution; D004359:Drug Therapy, Combination; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin